Now Reading
Novo Nordisk (CPH:NOVO.B) publishes 2008 Annual Report
Novo Nordisk (CPH:NOVO.B) publishes 2008 Annual Report
Published 02-04-09
Issued by Novo Nordisk
Summary
The report discusses key challenges & strategic initiatives to sustain long-term value creation. It also explains the company's way of doing business as a values-based company.
Report Highlights
Novo Nordisk, the world leader in diabetes care, is pleased to announce its fifth consecutive annual report with financial and non-financial performance in one inclusive document.
During fiscal year 2008, Novo Nordisk:
Increased sales by 12% (in local currencies) and by 9% in Danish kroner to DKK 45,553 million compared to the prior year. Increased reported operating profit by 38% to DKK 12,373 million compared to 2007. Maintained global leadership in diabetes care with 52% of the total insulin market. Reduced CO2 emissions by 9% and water consumption by 17%. Launched a programme to provide sustainable diabetes treatment for children in the world’s poorest countries.
The company’s 2008 report discusses key challenges and strategic initiatives to sustain long-term value creation. It also explains Novo Nordisk’s way of doing business as a values-based company.
Novo Nordisk’s reporting follows current international standards for mandatory and voluntary reporting:
International Financial Reporting Standards (IFRS). AA1000 Assurance Standard (2003). US Sarbanes–Oxley Act requirements for financial reporting. Novo Nordisk embarked in 2008 on a process of structuring the control environment for non-financial data with the aspiration to have full alignment with the control environment for financial data. The accountability standard, the AA1000 Framework. Global Reporting Initiative (GRI) G3 Sustainability Reporting Guidelines. UN Global Compact, Communication on Progress.
The report is available online, along with online information supplementing the report PDF, at annualreport2008.novonordisk.com.
About Novo Nordisk
Novo Nordisk is a world leader in diabetes care and has a leading position within haemostasis management, growth hormone therapy and hormone replacement therapy. The company employs more than 27,000 employees in 81 countries. Novo Nordisk’s B shares are listed on the stock exchanges in Copenhagen and London. Its ADRs are listed on the NYSE under the symbol ‘NVO’. For more information, visit www.novonordisk.com.
require_once 'counter/results/hit.php'; //hits counter do not remove
?>
Novo Nordisk
Novo Nordisk
Novo Nordisk is a global healthcare company with more than 90 years of innovation and leadership in diabetes care. The company also has leading positions within haemophilia care, growth hormone therapy and hormone replacement therapy. We believe that a healthy economy, environment and society are fundamental to long-term value creation. This is why we manage our business in accordance with the Triple Bottom Line business principle and consider the financial, environmental and social impact of our business decisions. The strategic commitment to corporate sustainability has brought the company onto centre stage as a leading player in today's business environment, recognised for its integrated reporting, stakeholder engagement and consistently high sustainability performance.